Rajputana Biodiesel has received a confirmed work order worth Rs 13.72 crore from Hindustan Petroleum Corporation Limited (HPCL) for the supply of 740 KL of Biodiesel each at Jaipur Terminal-MDPL, Rajasthan and Meerut, Uttar Pradesh.

Order In Financial Context

The Rs 13.72 crore order represents approximately 11.2% of the company's FY26 annual revenue of Rs 122.03 crore. When combined with the Rs 20.20 crore in orders disclosed in Q2FY27, the total disclosed order book for the last three fiscal quarters stands at Rs 33.92 crore (sum of the 3 orders disclosed across the last 3 fiscal quarters shown in the table below). This backlog provides visibility into near-term execution, though the specific quarterly average revenue figure required for precise book-to-bill calculation is not explicitly provided in the pre-computed metrics; however, the order value is material relative to the company's scale as an SME with a market cap of ₹139.26 Cr (as of 23 Sep 2026).

Company Order Track Record

The company has maintained steady inflow from major public sector oil marketing companies (OMCs). The current order size is consistent with the typical per-order value observed in the recent history, which ranges between Rs 8.37 crore and Rs 11.83 crore. The inflow velocity appears stable with two significant orders in Q2FY27 and one in Q3FY27.

Execution And Revenue Quality

The company's financial performance shows robust growth in top-line and bottom-line figures, with OPM stabilizing around 12-14%. However, the TTM P&L data provided shows zero revenue and profit, which likely indicates a data reporting lag or specific accounting treatment for the trailing period compared to the audited annual figures. Based on the latest annual data (FY26), the company reported Revenue of Rs 122.03 crore and Net Profit of Rs 10.42 crore, with an OPM of 12.34%.

Revenue Growth: Order Wins Translating To Revenue

As Rajputana Biodiesel has sustained order wins from major OMCs, its annual revenue has grown from Rs 68.60 crore in FY25 to Rs 122.03 crore in FY26, representing a YoY growth of +77.9% based on the latest annual data. This significant jump aligns with the increased order inflows visible in the recent quarters, suggesting that past contract acquisitions are effectively translating into recognized revenue.

Working Capital And Execution Capacity

The company's balance sheet indicates a Current Ratio of 2.04x, suggesting sufficient short-term liquidity to manage working capital cycles for the new orders. Total Liabilities/Equity stands at 0.83x, indicating a conservative leverage profile. However, operating cash flow remains negative at -Rs 15.30 crore in FY25, highlighting that while profits are reported, cash conversion is lagging, possibly due to stretched receivables or inventory build-up typical in commodity supply contracts.

What To Watch

• Execution Rate: Monitor quarterly revenue recognition against the Rs 33.92 crore total disclosed order book to ensure timely conversion.
• Margin Quality: Track OPM on these new orders against the historical average of ~12-14%, as input costs for biodiesel feedstock can impact margins.
• Client Concentration: HPCL, BPCL, and IOCL account for 100% of the disclosed order book in the last three quarters, indicating high client concentration among public sector entities.

Key Observations

• Valuation check (as of 23 Sep 2026): P/E of 13.0x against ROCE of 19.44%. At the time of this article, valuation was pricing in execution improvement not yet fully reflected in return ratios.
• Cash conversion: Operating cashflow of -Rs 15.30 crore in FY25; backlog is not converting to cash efficiently, and receivables or working capital cycle may be stretched.

WHAT HAPPENED

Rajputana Biodiesel received a Letter of Intent (LOI) valued at Rs 11.83 crore from Bharat Petroleum Corporation Limited (Bpcl). The scope covers execution during the period June 2026 to August 2026. This filing classifies the order as "Significant" but explicitly notes the terms are "As per the Letter of Intent," indicating that the full contract is not yet formalised. Revenue recognition for this value will begin only after the issuance of a formal work order or Letter of Award (LOA).

ORDER IN FINANCIAL CONTEXT

The Rs 11.83 crore LOI represents advance engineering or mobilisation costs rather than a firm contract value. When combined with the previous LOI of Rs 8.37 crore from Indian Oil Corporation Limited (Iocl), the total disclosed order book stands at Rs 20.20 crore (sum of the 2 orders disclosed across the last 3 fiscal quarters shown in the table below). Given the Trailing Twelve Month (TTM) revenue is currently reported as Rs 0.0 crore, the book-to-bill ratio cannot be computed on a trailing basis. However, relative to the average quarterly revenue derived from FY26 annual data (Rs 30.51 crore per quarter), the current backlog represents approximately 0.66 quarters of coverage. The critical metric here is the conversion rate: how quickly these LOIs translate into binding work orders that allow revenue booking.

COMPANY ORDER TRACK RECORD

Order inflow velocity appears stable, with two distinct LOIs secured in the current quarter from major public sector oil marketing companies. The consistency in per-order size (Rs 8.37 crore and Rs 11.83 crore) suggests the company is targeting mid-sized supply contracts within its operational capacity.

Note: The Rs 20.20 crore total includes the Rs 8.37 crore Iocl LOI dated July 21, 2026, and the Rs 11.83 crore Bpcl LOI dated July 27, 2026.

EXECUTION AND REVENUE QUALITY

The latest consolidated financials show zero revenue and profit for the trailing twelve months, likely reflecting the fiscal year transition period where full-year data has not yet been aggregated into the TTM window. Historical annual data provides better context for execution quality.

REVENUE GROWTH - ORDER WINS TRANSLATING TO REVENUE

As Rajputana Biodiesel has sustained order wins, with consistent LOIs from major oil marketing companies in Q2FY27, its annual revenue has grown from Rs 68.60 crore in FY25 to Rs 122.03 crore in FY26, representing a YoY growth of +77.9% based on the latest annual data. This historical growth trajectory supports the view that the company has the capacity to execute larger volumes, provided LOIs convert to firm contracts.

WORKING CAPITAL AND EXECUTION CAPACITY

The company’s balance sheet offers adequate liquidity to fund initial mobilisation. The current ratio stands at 2.04x, indicating sufficient current assets to cover short-term liabilities. Total Liabilities/Equity is 0.83x, which is well below the 2.0x threshold for elevated leverage concerns. However, operating cashflow was negative at -Rs 15.30 crore in FY25, suggesting that working capital cycles may be stretched or that cash outflows for inventory and capex are outpacing collections. Monitoring whether the new orders improve cash conversion efficiency is important.

WHAT TO WATCH

• Formal Work Order Issuance: The Rs 11.83 crore LOI must be converted into a formal Letter of Award (LOA) or Work Order before any revenue can be recognized. Delays in this process pose execution risk.
• Execution Rate: Monitor quarterly revenue run-rates against the total backlog. With TTM revenue at zero, the next few quarters will be critical in establishing the new revenue baseline.
• Cash Conversion: Operating cashflow has been negative for four consecutive years (FY22-FY25). Watch for improvement in free cashflow as new orders begin execution.
• Client Concentration: Both recent LOIs are from public sector undertakings (Bpcl and Iocl). While this reduces counterparty credit risk, it increases dependency on government procurement cycles.

KEY OBSERVATIONS

• Contract structure: This is a mobilisation / LNTP order. Revenue recognition begins only after formal work order issuance. The Rs 11.83 crore represents advance engineering costs, not the full contract value.
• Cash conversion: Operating cashflow of -Rs 15.30 crore in FY25; backlog is not converting to cash efficiently, and receivables or working capital cycle may be stretched.
• Valuation check (as of 29 Jul 2026): P/E of 13.1x against ROCE of 19.44%. At the time of this article, valuation was pricing in execution improvement not yet visible in return ratios. (P/E is price-derived and will change; ROCE is from audited financials)